Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
26.05.2023 - Positive high-level results from the DUO-E Phase III trial showed IMFINZI (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a ...
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating
The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.
NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent... | May 24, 2023
The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.